venBio Partners LLC Cuts Stock Holdings in Artiva Biotherapeutics, Inc. $ARTV

venBio Partners LLC lowered its stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) by 18.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 531,337 shares of the company’s stock after selling 117,170 shares during the period. Artiva Biotherapeutics makes up approximately 1.2% of venBio Partners LLC’s holdings, making the stock its 6th biggest position. venBio Partners LLC’s holdings in Artiva Biotherapeutics were worth $3,422,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Prelude Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $41,000. Bank of America Corp DE lifted its holdings in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth approximately $53,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $58,000. Finally, Jane Street Group LLC acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $67,000.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, SVP Heather Raymon sold 3,095 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $27,885.95. Following the sale, the senior vice president directly owned 148,228 shares of the company’s stock, valued at approximately $1,335,534.28. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Fred Aslan sold 27,116 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $244,315.16. Following the completion of the sale, the chief executive officer owned 1,535,082 shares in the company, valued at approximately $13,831,088.82. This represents a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have purchased 9,556,285 shares of company stock valued at $104,236,203 and have sold 53,040 shares valued at $477,890. Company insiders own 21.40% of the company’s stock.

Artiva Biotherapeutics Stock Up 2.9%

ARTV stock opened at $10.32 on Tuesday. The business’s 50-day simple moving average is $8.83 and its 200 day simple moving average is $7.37. The company has a market cap of $255.08 million, a PE ratio of -2.92 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ARTV shares. Wedbush boosted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.